Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Work In Process (2023 - 2025)

Tg Therapeutics has reported Work In Process over the past 3 years, most recently at $121.8 million for Q3 2025.

  • Quarterly results put Work In Process at $121.8 million for Q3 2025, up 62.47% from a year ago — trailing twelve months through Sep 2025 was $121.8 million (up 62.47% YoY), and the annual figure for FY2024 was $68.4 million, up 118.84%.
  • Work In Process for Q3 2025 was $121.8 million at Tg Therapeutics, down from $129.2 million in the prior quarter.
  • Over the last five years, Work In Process for TGTX hit a ceiling of $142.9 million in Q1 2025 and a floor of $27.1 million in Q1 2023.
  • Median Work In Process over the past 3 years was $74.1 million (2024), compared with a mean of $73.5 million.
  • Biggest five-year swings in Work In Process: soared 172.99% in 2024 and later skyrocketed 62.47% in 2025.
  • Tg Therapeutics' Work In Process stood at $31.2 million in 2023, then skyrocketed by 118.84% to $68.4 million in 2024, then surged by 78.16% to $121.8 million in 2025.
  • The last three reported values for Work In Process were $121.8 million (Q3 2025), $129.2 million (Q2 2025), and $142.9 million (Q1 2025) per Business Quant data.